Christopher Powala
2015
In 2015, Christopher Powala earned a total compensation of $2.4M as Chief Operating Officer at Aclaris Therapeutics, a 404% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $91,581 |
|---|---|
| Option Awards | $1,838,108 |
| Salary | $305,271 |
| Stock Awards | $186,420 |
| Other | $11,948 |
| Total | $2,433,328 |
Powala received $1.8M in option awards, accounting for 76% of the total pay in 2015.
Powala also received $91.6K in non-equity incentive plan, $305.3K in salary, $186.4K in stock awards and $11.9K in other compensation.
Rankings
In 2015, Christopher Powala's compensation ranked 3,946th out of 13,638 executives tracked by ExecPay. In other words, Powala earned more than 71.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,946 out of 13,638 | 71st |
Division Manufacturing | 1,438 out of 5,190 | 72nd |
Major group Chemicals And Allied Products | 521 out of 1,854 | 72nd |
Industry group Drugs | 414 out of 1,528 | 73rd |
Industry Pharmaceutical Preparations | 327 out of 1,182 | 72nd |
Source: SEC filing on April 21, 2017.
Powala's colleagues
We found two more compensation records of executives who worked with Christopher Powala at Aclaris Therapeutics in 2015.